Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis

Jean Paul Ortonne*, Mark Lebwohl, Christopher Em Griffiths, Kirk Barber, Eileen Murray, Marc Bourcier, Wayne Gulliver, Richard Langley, Lynn Guenther, Kim Papp, Jerry Tan, Yves Poulin, Michel Heenen, Julien Lambert, Michel De La Brassine, Knud Kragballe, Frederik Grönhöj-Larsen, Philippe Humbert, Gerard Guillet, Pierre ThomasJean Luc Schmutz, Louis Dubertret, Gerard Lorette, Wolfram Sterry, Peter Altmeyer, Gottfried Wozel, Enno Christophers, Gustav Mahrle, Uwe Frithjof Haustein, Gerd Plewig, Thomas Luger, Mario Leicha, Maximiliano Aragües, Adolpho Aliaga, J. D. Bos, Peter Van De Kerkhof, Arnold Oranje, James Ferguson, Lesley Rhodes, Jonathan Barker, Dow Stough, Regina Hamlin, Stacy Smith, Margaret Drehobl, Nick Lowe, Robert Brown, Christopher Nelson, James Aton, Mark Ling, Kenneth Gordon, Donald Belsito, Daniel Stewart, Craig Leonardi, Michael Heffernan, Thomas Casale, David Hassman, Diane Baker, Janet Roberts, Harold Farber, Ellen Frankel, Keith Loven, Hans Sander, Peter Hino, John Gonzalez, Thomas Nigra

*Corresponding author for this work

Research output: Contribution to journalArticle

57 Scopus citations

Abstract

This international, double-blind study examined the effects of alefacept on circulating lymphocytes in 507 patients with chronic plaque psoriasis, and determined whether these effects were related to clinical improvement. Patients were randomized to intramuscular placebo, alefacept 10 mg, or alefacept 15 mg once weekly for 12 weeks followed by 12 weeks of observation. Alefacept dose-dependently reduced CD4+ and CD8+ memory T cells, while sparing the naïve population. The greatest reductions in disease activity occurred in patients with the largest decreases in memory T cells. For example, a ≥ 50% reduction from baseline Psoriasis Area Severity Index at any time during treatment or follow-up was observed in 66% of patients who had the greatest reductions in CD4+ memory T cells versus in 40% of patients who had the smallest reductions in this T-cell subset. These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalEuropean Journal of Dermatology
Volume13
Issue number2
StatePublished - Mar 2003

Keywords

  • Alefacept
  • Amevive®
  • Efficacy
  • Pharmacodynamics
  • Psoriasis
  • T lymphocytes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis'. Together they form a unique fingerprint.

  • Cite this

    Ortonne, J. P., Lebwohl, M., Em Griffiths, C., Barber, K., Murray, E., Bourcier, M., Gulliver, W., Langley, R., Guenther, L., Papp, K., Tan, J., Poulin, Y., Heenen, M., Lambert, J., De La Brassine, M., Kragballe, K., Grönhöj-Larsen, F., Humbert, P., Guillet, G., ... Nigra, T. (2003). Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. European Journal of Dermatology, 13(2), 117-123.